glp-1 and dementia Adults whose type 2 diabetes was treated with receptor agonists were more likely to develop cognitive impairment over 10 years than their counterparts not treated with GLP-1 agents, a propensity-matched retrospective NEW STUDY: GLP-1 meds slash

Opportunity Pathways - GLP-1 Diabetes Treatment Drugs Market The GLP-1 diabetes treatment drugs market represents one of the most explosive pharmaceutical opportunities of the decade, with the market projected to surge from USD 6,556.5 million in 2025 to USD 62,543.2 million by 2035 at an extraordinary 25.3% CAGRa 9.5X expansion driven by the global diabetes epidemic, breakthrough efficacy data, and expanding therapeutic applications beyond glucose control to include weight management and cardiovascular protection

Most protocols then step up to 200 mcg per shot

Cell 170 , 678692.e20 (2017)

Pasteurized Akkermansia MucT

They have built a solid reputation in the peptide community